VU6028418

VU6028418
Identifiers
	IUPAC name (3aS,6aR)-2-(oxan-4-ylmethyl)-N-[6-(2,3,5-trifluorophenyl)pyridazin-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-amine;
CAS Number	2649803-05-2;
PubChem CID	164606754;
ChemSpider	129431227;
ChEMBL	ChEMBL4850236;
Chemical and physical data
Formula	C23H27F3N4O
Molar mass	432.491 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COCCC1CN2C[C@H]3CC(C[C@H]3C2)NC4=NN=C(C=C4)C5=C(C(=CC(=C5)F)F)F;
	InChI InChI=1S/C23H27F3N4O/c24-17-9-19(23(26)20(25)10-17)21-1-2-22(29-28-21)27-18-7-15-12-30(13-16(15)8-18)11-14-3-5-31-6-4-14/h1-2,9-10,14-16,18H,3-8,11-13H2,(H,27,29)/t15-,16+,18?; Key:ITSKPCHXUYILTR-BYICEURKSA-N;

VU6028418 is an experimental drug that acts as a potent and selective antagonist of the Muscarinic acetylcholine receptor M4. It has been investigated for the treatment of dystonia and other movement disorders.^[1]

References

^ Spock M, Carter TR, Bollinger KA, Han C, Baker LA, Rodriguez AL, et al. (August 2021). "Discovery of VU6028418: A Highly Selective and Orally Bioavailable M₄ Muscarinic Acetylcholine Receptor Antagonist". ACS Medicinal Chemistry Letters. 12 (8): 1342–1349. doi:10.1021/acsmedchemlett.1c00363. PMC 8366002. PMID 34413964.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Spock M, Carter TR, Bollinger KA, Han C, Baker LA, Rodriguez AL, et al. (August 2021). "Discovery of VU6028418: A Highly Selective and Orally Bioavailable M₄ Muscarinic Acetylcholine Receptor Antagonist". ACS Medicinal Chemistry Letters. 12 (8): 1342–1349. doi:10.1021/acsmedchemlett.1c00363. PMC 8366002. PMID 34413964.

[1]